GLPwatch
Papers (9189)
Page 139 of 154, ranked by citation count.
- Comparative effectiveness of semaglutide and dulaglutide combined with hypocaloric diet in newly diagnosed type 2 diabetes: a retrospective real-world study.
- Efficacy and Safety of Tirzepatide and Semaglutide for Obesity Management: A Real-World Comparison.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
- Comparative Renal Safety of Tirzepatide and Semaglutide: An FDA Adverse Event Reporting System (FAERS)-Disproportionality Study.
- Association Between Semaglutide or Tirzepatide Therapy and Residual Gastric Content: A Potential Danger During Upper Endoscopy.
- Correction: Metabolic resilience: liraglutide's potential in alleviating depressive symptoms.
- Comparative Effects of Dulaglutide and Semaglutide on Renal Function Decline and Proteinuria Reduction in Diabetic Patients: A Retrospective Cohort Study.
- Comparative Efficacy and Safety of Tirzepatide Versus Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
- [IDegLira receives extended approval].
- [Cardiac effects of glucagon-like peptide 1].
- Influence of Hydrophobic Ion Pairing on Formulation Performance of Liraglutide in PLGA Microspheres.
- Mental health outcomes in obesity interventions with GLP-1 receptor agonists: is it similar to other obesity interventions? A narrative review with systematic evidence synthesis.
- An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon-like peptide-1 and glucagon receptor in healthy subjects.
- Meta-analysis of clinically available pharmacotherapy of biopsy confirmed metabolic dysfunction associated steatohepatitis (MASH).
- Simultaneous Versus Sequential Initiation of Lixisenatide and Basal Insulin for Type 2 Diabetes: Subgroup Analysis of a Japanese Post-Marketing Surveillance Study of Lixisenatide (PRANDIAL).
- Effectiveness and safety of once-weekly semaglutide: findings from the SEMACOL-REAL retrospective multicentric observational study in Colombia.
- Rationale, Design, and Baseline Characteristics of the TRANSCEND-CKD trial of Retatrutide in Patients with Chronic Kidney Disease.
- Meta-analysis of the Effect of Semaglutide on Blood Pressure in Obese Populations.
- Injections vs. Scalpels: Where Do Surgery and GLP-1's Align in Modern Obesity treatment?
- Exploring the cardiopulmonary effects of tirzepatide in atrial fibrillation and comorbid chronic obstructive pulmonary disease.
- Development of a Long-Acting and Stapled Dual Amylin and Calcitonin Receptor Agonist as Monotherapy and Combination with GLP-1R Agonists for the Treatment of Obesity.
- Metformin-Enhanced Digital Therapeutics for the Affordable Primary Prevention of Diabetes and Cardiovascular Diseases: Advancing Low-Cost Solutions for Lifestyle-Related Chronic Disorders.
- [Obesity as a chronic disease: the key role of new therapies].
- [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
- Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis.
- Effectiveness and Safety of Antidiabetic Medications in Hidradenitis Suppurativa: A Systematic Review.
- Evaluating the pharmacotherapy of tirzepatide in patients with type 2 diabetes: The consideration of systemic metabolism.
- The Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists in Psoriasis and Hidradenitis Suppurativa.
- Cardiovascular Outcomes and Safety of GLP-1 Receptor Agonists in Elderly Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
- Appetite, Obesity, Metabolism, and Malignancy: Do Incretin-Mimetic Drugs Reduce Cancer Risk?
- Responses to GLP-1RA in White and Black Adults With Obesity: Insights From Generalized Additive Mixed Models of EHR Data.
- Clinical Advances in Heart Failure with Preserved Ejection Fraction: A Systematic Review of Therapeutic and Mechanistic Evidence.
- Metabolic and Bariatric Surgery vs Glucagon-like peptide-1 Receptor Agonist Therapy: A Head-to-Head Comparison in Improvement of Cardiometabolic Risk Profiles.
- [Extrapancreatic effects of GLP-1 receptor agonists: an open window towards new treatment goals in type 2 diabetes].
- Tirzepatide reverses hypothalamic inflammation, cellular stress, and neuropeptide imbalance in metabolic-menopausal dysfunction.
- Drug-induced liver injury secondary to tirzepatide.
- Mediterranean diet adherence and tirzepatide: real-world evidence on adiposity indices and insulin resistance beyond weight loss.
- Legal Challenges to Compounding Drugs for Weight Loss.
- [Degludec/liraglutide] fixed combination as a therapy alternative].
- [The antidiabetic drug liraglutide lowers risk of cardiac death].
- Glucagon-like Peptide-1 Receptor Agonists in Liver Transplant Recipients: A Retrospective Cohort Study.
- [in process].
- GLP1-1RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta-analysis of randomised controlled trials and cohort studies.
- Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated glucagon-like peptide 1 receptor agonists.
- Tirzepatide-Induced Liver Injury: A Rare Complication.
- Retatrutide in type 2 diabetes mellitus and obesity: an overview.
- Cardiovascular Outcomes in Adults With Type 2 Diabetes Treated With Tirzepatide: A Systematic Review and Meta-Analysis of Real-World Studies.
- Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes.
- Oral GLP-1 receptor agonists for the treatment of obesity: ATTAINing metabolic benefits to find the OASIS.
- Development and validation of an LC-MS/MS method for Tirzepatide, a dual GIP/GLP-1 receptor agonist, in rat plasma for application to a pharmacokinetic study.
- Challenges in the management of obesity.
- Metformin provides superior neuroprotective potential compared to semaglutide in preventing diabetes-associated Alzheimer's disease via dual actions.
- Documentation of Compounded GLP-1 Receptor Agonists in a Large Primary Care Dataset.
- [Glucagon-like peptide 1 agonists : the fourth pillar of nephroprotection in type 2 diabetes].
- Management of Obesity in Psoriasis Consultations.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
- Rebound or Retention: A Meta-Analysis of Weight Regain After the Discontinuation of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Other Anti-obesity Drugs.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
- Economic Evaluation of Medications in Prevention and Treatment of Obesity: A Systematic Review.